Since 2007, the Administrative Core has deftly identified and accomplished tasks related to the operation and success of this P01 through two granting cycles. This experience will be leveraged in the next granting cycle to permit the P01 leadership to again use the Administrative Core as the primary means to assure continuous integration and interaction among all P01 components and to oversee the research projects and other cores. This Core facilitates rapid communication and connection among investigators, projects, and cores through face-to-face meetings, written reports, and electronic communication. This Core assists sharing our research data with investigators both within and outside of Memorial Sloan Kettering (MSK) with a special emphasis to link Dr. Lovly and her Project 3 team at Vanderbilt with all facets of the program project through electronic communication and videoconferencing. The Administrative Core provides (1) administrative services; regulatory and reporting services, including preparation of annual reports and renewals; (2) budget management; (3) publication management and oversight; (4) videoconferencing for all P01 activities; (6) scheduling of P01 work-in-progress conferences for the investigators and yearly face-to-face presentations to our advisory committees; and (6) support of the oversight activities of the Executive and Advisory committees. The Administrative Core centralizes, expands, and improves the operational capabilities of the individual research projects and cores, avoids duplication, and ensures optimum utilization of resources. The MSK Lung P01 Program Manager supported by this Core meets at least 4 times a year with the Principal Investigators and the Executive Committee to assist in monitoring operations so that the research supported by the program project proceeds efficiently. The MSK Lung P01 Program Manager, with Drs Kris and Ladanyi, prepares and distributes a yearly progress report for the Executive and the Scientific Advisory Committees to assist in their review and oversight. The Administrative Core supports the Project and Core Leaders, the Executive Committee, and the Advisory Committees. It provides services that are essential for the P01 to function as an integrated research program to develop new targets for treatment for persons with lung cancers.
Lung cancers are America?s leading cancer killers, responsible for 158,000 deaths this year. This grant addresses two critical roadblocks to improving the care and curability of persons with these illnesses: understanding how cancers spread (metastasis) and the lack of medicines to prevent spread or to eradicate cancers that have spread from the lungs. The Administrative Core unites, integrates, and evaluates the components of this P01 is critical to this effort.
|Yu, Helena A; Perez, Leslie; Chang, Qing et al. (2017) A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib. J Thorac Oncol 12:102-109|
|Ichihara, Eiki; Westover, David; Meador, Catherine B et al. (2017) SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Res 77:2990-3000|
|Yaeger, Rona; Yao, Zhan; Hyman, David M et al. (2017) Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Res 77:6513-6523|
|Weigelt, Britta; Comino-Méndez, Iñaki; de Bruijn, Ino et al. (2017) Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res 23:6708-6720|
|Pal, Debjani; Pertot, Anja; Shirole, Nitin H et al. (2017) TGF-? reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells. Elife 6:|
|Yu, H A; Sima, C; Feldman, D et al. (2017) Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol 28:278-284|
|Boire, Adrienne; Zou, Yilong; Shieh, Jason et al. (2017) Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis. Cell 168:1101-1113.e13|
|Nieto, Patricia; Ambrogio, Chiara; Esteban-Burgos, Laura et al. (2017) A Braf kinase-inactive mutant induces lung adenocarcinoma. Nature 548:239-243|
|Yao, Zhan; Yaeger, Rona; Rodrik-Outmezguine, Vanessa S et al. (2017) Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548:234-238|
|Drilon, Alexander; Somwar, Romel; Wagner, Jacob P et al. (2016) A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clin Cancer Res 22:2351-8|
Showing the most recent 10 out of 168 publications